Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Jaguar Health Achieves Key Milestone for Crofelemer API Manufacturer | Contract Pharma
Breaking News

Jaguar Health Achieves Key Milestone for Crofelemer API Manufacturer

Supports the expansion of manufacturing volume required for potential additional indications for crofelemer.

Jaguar Health, Inc. has successfully completed the registration of the source of the active pharmaceutical ingredient (API) of crofelemer with the Agenzia Italiana Del Farmaco (AIFA), the Italian Medicines Agency. As a result, batches of crofelemer API manufactured by Milan, Italy-based Indena S.P.A. can now be used by Jaguar for further development work.
 
“We are very pleased about the completion of this key milestone in the ongoing process of establishing Indena as an additional approved crofelemer manufacturer as we work to support the increased crofelemer manufacturing demand expected upon potential FDA approval of crofelemer for new indications, including approval for cancer therapy-related diarrhea (CTD),” said David Sesin, Ph.D., Jaguar’s chief manufacturing officer. “Jaguar is honored to have had a long-standing relationship with Indena, a pioneer and world-class leader in plant-based pharmaceutical manufacturing.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters